Clovis Oncology Inc (CLVS) : Antipodean Advisors reduced its stake in Clovis Oncology Inc by 16.45% during the most recent quarter end. The investment management company now holds a total of 1,059,901 shares of Clovis Oncology Inc which is valued at $17,880,530 after selling 208,757 shares in Clovis Oncology Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Clovis Oncology Inc makes up approximately 7.36% of Antipodean Advisors’s portfolio.
Other Hedge Funds, Including , Group One Trading sold out all of its stake in CLVS during the most recent quarter. The investment firm sold 18,816 shares of CLVS which is valued $317,426.Rhumbline Advisers boosted its stake in CLVS in the latest quarter, The investment management firm added 3,020 additional shares and now holds a total of 34,047 shares of Clovis Oncology Inc which is valued at $574,373. Credit Agricole S A sold out all of its stake in CLVS during the most recent quarter. The investment firm sold 4,344 shares of CLVS which is valued $73,283. Thompson Davis added CLVS to its portfolio by purchasing 125 company shares during the most recent quarter which is valued at $1,961.
Clovis Oncology Inc closed down -1.18 points or -4.76% at $23.59 with 27,16,679 shares getting traded on Thursday. Post opening the session at $25.01, the shares hit an intraday low of $23.138 and an intraday high of $25.3 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Clovis Oncology Inc reported $-2.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-2.11.During the same quarter in the previous year, the company posted $-2.10 EPS.
Many Wall Street Analysts have commented on Clovis Oncology Inc. Company shares were Reiterated by Mizuho on Aug 24, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $15 .Clovis Oncology Inc was Initiated by SunTrust to “Buy” on Aug 5, 2016.
Clovis Oncology Inc. (Clovis) is a biopharmaceutical company focused on acquiring developing and commercializing anti-cancer agents in the United States Europe and additional international markets. The Company is developing three product candidates: Rociletinib Rucaparib and Lucitanib. Rociletinib an oral epidermal growth factor receptor (EGFR) is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib an oral inhibitor of poly (ADP-ribose) polymerase (PARP) is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3) vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.